The partnership will also involve the implementation of a cutting-edge management system for dairy farms, a prototype that will serve as a model for managing a commercial dairy operation without the routine use of antibiotics during the dry period and lactation
Mileutis, an Israeli biopharmaceutical company, has announced a significant investment and expanded collaboration with Yotvata Dairy. As part of the new agreement, Yotvata Dairy Farm will invest millions of New Israeli Shekels in the Israeli company, signalling a commitment to achieve significant improvement in sustainability and milk quality. Yotvata has also stated its intention to replace the use of antibiotics for the treatment and prevention of infections with Imilac therapy in the Israeli dairy farms that supply it with milk. The project is led by Yotvata Dairy, Yotvata Dairy Farm and additional dairy farms which provide milk to Yotvata Dairy.
The partnership will also involve the implementation of a cutting-edge management system for dairy farms, a prototype that will serve as a model for managing a commercial dairy operation without the routine use of antibiotics during the dry period and lactation. This approach aligns with Mileutis mission to redefine the dairy industry, moving away from traditional reliance on antibiotics and towards more sustainable and environmentally friendly practices.
The partnership follows a successful clinical trial conducted in collaboration with Yotvata, where Mileutis’ flagship product, Imilac, demonstrated its effectiveness in replacing the use of antibiotics in dairy cows when administered at dry-off. The trial, which involved over 500 cows across seven large Israeli dairy farms, in addition to showing the ability of Imilac to replace the routine use of antibiotics as a dry-off therapy, demonstrated Imilac’s ability to increase milk quality and milk yield.
